Home | News | Contact Us

 

 

About Us Advisors FBLD Programs Partnering Products    
               
 
Zenobia Therapeutics is dedicated to finding cures for unmet medical needs

Fragment Library

Information

 
  • G2019S LRRK2 Parkinson's Disease program

  • ALK Neuroblastoma program

We are pioneers in the field of Fragment-based Lead Discovery

  • Founders are inventors of crystallographic and NMR-based screening

  • Team has contributed to four FBLD derived IND

We have adapted FBLD to address key challenges in CNS drug discovery

  • Custom CNS directed fragment library

  • Computational tools engineering CNS compatible physiochemical properties

We offer FBLD services

  • Commercial fragment library collections

  • Fragment-screening and lead discovery

  • x-ray crystallography

 

Recent News

06/22/2010
Omscientia to distribute Zenobia Fragment Library
10/01/2009
Zenobia featured in
Neurotech insights
05/08/2009
Zenobia featured in Bioworld Today
04/22/2009
Zenobia featured in Xconomy
04/13/2009
Zenobia successfully completes initial phase of its service agreement with Syntonix Pharmaceuticals
03/01/2009
Zenobia announces sale of commercial fragment library ideal for crystallographic, NMR and SPR screening
 
07/29/2008
Zenobia announces receipt of a M.J.Fox Parkinson's disease Therapeutics Development Initiative grant